Does immune inflammatory signaling activate IDO and shift tryptophan metabolism toward kynurenine and quinolinic acid?

In aging individuals, chronic low-grade inflammation is a major driver of altered brain chemistry and metabolic shifts. A primary mediator of this process is the enzyme indoleamine 2,3-dioxygenase (IDO), which redirects amino acid pathways in response to immune activation.

Mechanistic activation of IDO

• Pro-inflammatory signaling, particularly via interferon-gamma (IFN-γ), binds to its receptor to initiate the canonical JAK-STAT signaling pathway.
• Phosphorylated STAT1 dimerizes and translocates to the nucleus, binding gamma-activated sequence (GAS) elements in the IDO1 promoter to upregulate transcription, a process further enhanced by interferon regulatory factor-1 (IRF-1).
• Other cytokines, such as TNF-α, IL-1β, and IL-6, synergize through NF-κB and MAPK pathways to drastically accelerate IDO1 enzymatic expression.

The metabolic kynurenine shunt

• Elevated IDO activity shunts tryptophan degradation away from the production of serotonin and its primary metabolite, 5-hydroxyindoleacetic acid (5-HIAA).
• This diversion increases the synthesis of kynurenine and its downstream metabolite, quinolinic acid, a potent NMDA receptor agonist that induces excitotoxicity, oxidative stress, and neurotoxicity.
• Furthermore, accumulated kynurenine acts as an endogenous ligand for the Aryl hydrocarbon receptor (AhR), driving downstream immunosuppressive transcriptional programs.
• This metabolic imbalance is clinically indexed by an elevated quinolinic acid to 5-HIAA ratio, representing a state of neuroinflammatory vulnerability.

Bottom line

• Key takeaway: Immune inflammatory signaling via the JAK-STAT and NF-κB pathways directly upregulates IDO, diverting tryptophan metabolism away from serotonin synthesis and toward the production of neurotoxic quinolinic acid.